Fate Therapeutics (FATE) Competitors $1.13 -0.01 (-0.88%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.44%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRAShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors aTyr Pharma Siga Technologies Tourmaline Bio Cullinan Therapeutics MBX Biosciences Rezolute Kamada Terns Pharmaceuticals REGENXBIO Savara Fate Therapeutics (NASDAQ:FATE) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Is FATE or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% aTyr Pharma N/A -87.09%-64.77% Do analysts prefer FATE or ATYR? Fate Therapeutics currently has a consensus price target of $3.83, suggesting a potential upside of 239.23%. aTyr Pharma has a consensus price target of $20.20, suggesting a potential upside of 258.79%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do institutionals and insiders hold more shares of FATE or ATYR? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor FATE or ATYR? In the previous week, Fate Therapeutics had 3 more articles in the media than aTyr Pharma. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.83 beat Fate Therapeutics' score of 0.44 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Overall Sentiment Fate Therapeutics Neutral aTyr Pharma Positive Which has preferable earnings and valuation, FATE or ATYR? aTyr Pharma has lower revenue, but higher earnings than Fate Therapeutics. aTyr Pharma is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.50-$186.26M-$1.49-0.76aTyr Pharma$230K2,178.57-$64.02M-$0.81-6.95 Which has more risk and volatility, FATE or ATYR? Fate Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. SummaryaTyr Pharma beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.65M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.7620.2228.5419.58Price / Sales9.50299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.407.568.145.54Net Income-$186.26M-$55.11M$3.24B$257.73M7 Day Performance-1.74%3.81%0.18%-0.08%1 Month Performance-8.87%11.60%5.96%8.09%1 Year Performance-75.16%-2.11%26.24%13.02% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.6217 of 5 stars$1.13-0.9%$3.83+239.2%-71.0%$130.65M$13.63M-0.76550ATYRaTyr Pharma2.0517 of 5 stars$5.53+4.3%$20.20+265.3%+219.0%$492.17M$230K-6.8353SIGASiga Technologies2.2192 of 5 stars$6.86+1.3%N/A-26.6%$490.08M$138.72M10.2440News CoverageTRMLTourmaline Bio2.0331 of 5 stars$18.96+5.5%$49.33+160.2%+22.0%$486.99MN/A-5.9144News CoveragePositive NewsCGEMCullinan Therapeutics1.7317 of 5 stars$7.87+2.2%$30.00+281.2%-55.1%$464.41MN/A-2.7030News CoverageMBXMBX Biosciences1.7028 of 5 stars$13.87+6.4%$37.50+170.4%N/A$463.59MN/A0.0036RZLTRezolute2.3985 of 5 stars$5.32+1.1%$11.83+122.4%+5.4%$454.97MN/A-4.6340KMDAKamada4.3088 of 5 stars$7.78+0.4%$13.00+67.1%+30.8%$447.39M$167.24M26.83360Positive NewsTERNTerns Pharmaceuticals3.8293 of 5 stars$5.11+4.3%$15.63+205.8%-49.4%$446.31MN/A-4.6940RGNXREGENXBIO3.9988 of 5 stars$8.70+0.2%$31.63+263.5%-36.0%$436.39M$83.33M-2.80370SVRASavara2.1685 of 5 stars$2.51+5.0%$5.60+123.1%-53.7%$433.83MN/A-5.2320 Related Companies and Tools Related Companies aTyr Pharma Alternatives Siga Technologies Alternatives Tourmaline Bio Alternatives Cullinan Therapeutics Alternatives MBX Biosciences Alternatives Rezolute Alternatives Kamada Alternatives Terns Pharmaceuticals Alternatives REGENXBIO Alternatives Savara Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts